NR

NR is a pyridine nucleoside consisting of nicotinamide attached to a ribose sugar, and it is recognized as a form of vitamin B3 ^[1]. After entering cells it is phosphorylated by nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide, which is then converted to NAD+, giving NR a distinct entry point into NAD+ synthesis ^[1][4]. NAD+ itself is indispensable for the redox reactions of energy metabolism and serves as a co-substrate for sirtuins and other repair enzymes whose activity is linked to healthy aging ^[4].

Human pharmacokinetic work established that NR is efficiently taken up after oral dosing; a first-in-human study showed that single doses produced dose-dependent increases in the blood NAD+ metabolome and identified a sensitive biomarker of NAD+ repletion ^[1]. Longer trials confirmed durability and tolerability; chronic NR supplementation was well tolerated and effectively elevated NAD+ in healthy middle-aged and older adults, with preliminary signals for lower blood pressure and arterial stiffness ^[2]. A randomized trial in overweight adults likewise found that NR dose-dependently raised whole-blood NAD+ over eight weeks without significant adverse effects or lipid disturbances ^[3]. As with NMN, robust proof of downstream health or longevity benefits in humans remains limited.

Commercially, NR is sold chiefly as nicotinamide riboside chloride, marketed under the trademark Niagen, which was accepted by the United States Food and Drug Administration as generally recognized as safe in 2016 and later authorized for use in food supplements in the European Union ^[3]. It is available over the counter, typically in capsules or tablets. Its comparatively clear regulatory standing distinguishes it from NMN, whose supplement status has been more contested.

NR has a strong human safety record, generally well tolerated with few side effects at common doses. Occasional mild nausea, flushing, or GI upset can occur. Long-term outcome data is still limited, but its safety profile is among the best studied of the NAD+ precursors.

Nicotinamide riboside is a naturally occurring pyridine nucleoside and a precursor to nicotinamide adenine dinucleotide (NAD+). Although present in trace amounts in foods such as milk, its significance was clarified in 2004 when Charles Brenner and colleagues identified a conserved nicotinamide riboside kinase pathway that converts it into NAD+ in yeast and humans. This discovery reframed the molecule as a distinct vitamin B3 form and spurred interest in using it to counter the decline in NAD+ associated with aging. It was later commercialized, most prominently as the branded ingredient Niagen developed by ChromaDex, and became a widely studied nutritional NAD+ booster.

Nicotinamide riboside is one of the most popular supplements in the longevity and mitochondrial-health space, promoted heavily on the promise of restoring cellular NAD+ levels. Human trials have fairly consistently shown that it does raise blood NAD+ and that it is well tolerated, which supports its reputation as a safe and biologically active compound. However, the community is divided on whether these biochemical changes translate into meaningful improvements in energy, cognition, or aging outcomes, since clinical benefits have often been small or inconsistent. As a result it is viewed as promising and mechanistically credible but with functional claims that outpace the current evidence.